Since the MDR cell line variants of SCLC model in the article above were developed by stepwise increments of chemotherapeutics, there is a concern that the results might have been affected from various changes other than P-gp that the cell line variants might have acquired during this lengthy period. The gene discussed is PGP; the disease is small cell lung carcinoma.